CGTN
30.10.2020 04:15:07 CET | Business Wire | Press release
The 19th Central Committee of the Communist Party of China (CPC) concluded its fifth plenary session in Beijing on Thursday with the release of a communique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006395/en/
The 14th Five-Year Plan (FYP) (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035 are the key topics of the communique.
Here is a look at all the highlights from the communique of the meeting.
Read the original article: here .
Decisive success made in building a moderately prosperous society in all respects
This year is the final year of China's 13th FYP period (2016-2020) and the communique highlighted that the implementation of the 13th FYP has been smooth.
By adhering to the new development concept and unswervingly advancing reform and opening-up, great achievements have been made since the fourth plenary session, the communique said.
During the past year, China has deepened supply-side reform, enhanced macro-economic regulation and expanded domestic demand as the strategic foundation.
Economic growth has been better than expected, people's livelihood has been improved and social stability has been maintained.
During the 13th FYP period, which is coming to an end in 2020, China has made great progress with stable economic growth and better economic structure, the communique said, noting China's GDP is expected to surpass the 100 trillion yuan ($14.9 trillion) mark in 2020.
More than 55 million people in China have been lifted out of poverty in the past five years.
China has built the world's largest social security system in the 13th FYP period, the communique said, adding that the country's basic medical insurance has covered over 1.3 billion people, and basic old-age insurance has covered nearly 1 billion people.
Meanwhile, during the past five years, more than 60 million new jobs were created in China's urban areas, it said.
As for the fight against the COVID-19 pandemic, the whole country coordinated the prevention and control work with economic and social development and put people's safety and health first.
Major country diplomacy with Chinese characteristics was vigorously promoted, and major achievements were made in various undertakings of the Party and state.
The strength of the leadership of the CPC and the Chinese socialist system has been further demonstrated in the past five years, it added.
New challenges, opportunities and proposals ahead
With regards to the blueprint for the future, the communique stressed that the whole Party must take into account the overall strategic plan for the great rejuvenation of the Chinese nation with major changes in the world that have not occurred in a century.
A thorough understanding is necessary about the new characteristics and requirements brought about by the changes in the evolution of the principal contradiction facing Chinese society, it said.
Also, given that China is in the primary stage of socialism, more attention should be paid to the new contradictions and challenges brought by the complex international environment.
The communique underlined the importance of strengthening awareness of opportunities and risks and cultivating opportunities amid crisis.
Additionally, the CPC has raised a set of long-range objectives for China to achieve socialist modernization by 2035.
China's economic, technological and composite strength was also stressed, as well as development in new industrialization and the modernization of China's system and capacity for governance.
The communique also said effort was needed in boosting the well-rounded development of society, including social etiquette and civility and the advancement of eco-friendly ways of work and life.
China's opening-up, per capita GDP, the implementation of the Peaceful China initiative and well-rounded human development were also highlighted.
As for the goals to be reached during the 14 FYP period, the communique said that the overall leadership of the CPC must be upheld to realize the 14th FYP and efforts should be made to mobilize all positive factors and rally all the forces that can be rallied to form a strong synergy to promote development.
Several proposals to reach the goals
- Upholding the central role of innovation in its modernization drive and implementing the innovation-driven strategy.
- Building a modern industrial system and upgrading the economic structure. It will continue to support the real economy, improve manufacturing power and modernized industrial chain and supply chain, so as to improve high-quality growth and core competitiveness.
- Nurturing a strong domestic market and establishing a new development pattern. The country will smooth domestic circulation and let domestic and international circulations reinforce each other, spurring consumption in an all-round way and expanding investment.
- Deepening reform comprehensively in pursuit of a high-level socialist market economy.
- Prioritizing the development of agriculture and rural areas, and fully advancing rural vitalization.
- Advancing coordinated regional development and a new type of urbanization.
- Promoting cultural sector and improving its cultural soft power.
- Accelerating green and low-carbon development, continuously improving the environment as well as the quality and stability of ecosystems, and raising the efficiency of resource utilization.
- Pursuing high-level opening-up and exploring new prospects of win-win cooperation.
It will continue to widen the opening-up and leverage the advantages of its huge market to promote international cooperation and achieve win-win results.
- Improving people's standard of living, and actively implementing strategies to address ageing population.
- Strengthening national security capabilities and increasing the capacity to deal with traditional and non-traditional security challenges, so as to protect people's lives and security and maintain social stability.
- Maintaining the long-term prosperity and stability of the Hong Kong and Macao special administrative regions, and promoting the reunification of Chinese mainland and Taiwan as well as peaceful Cross-Strait development.
It aims to keep a stable external environment and promote the building of a new type of international relations and a community with a shared future for mankind.
A total of 198 members and 166 alternate members of the CPC Central Committee attended the meeting.
Also present were members of the Standing Committee of the CPC Central Commission for Discipline Inspection and senior officials of relevant sectors, as well as experts, scholars and several deputies of the 19th CPC National Congress who work at the grassroots level.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006395/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
